Trastuzumab Duocarmazine Active in HER2-Positive Breast Cancer
The HER2-targeting antibody-drug conjugate (vic-)trastuzumab duocarmazine (SYD985) showed promising clinical activity in heavily-pretreated women with metastatic breast cancer.
Source: OncLive